Abstract
Subependymal giant cell astrocytoma (SEGA) is the most common central nervous system tumor in patients with tuberous sclerosis complex (TSC). Although SEGA is a generally benign tumor (WHO grade Ⅰ), it gives rise to focal neurological deficit and obstructive hydrocephalus. At this point, surgical removal is the standard treatment of SEGA. But not all SEGA could be safely and completely resectable. Gamma knife radiosurgery is another option for the primary or adjuvant treatment for SEGA. Because of highly variable response and possibility of adverse effect, we need larger patient populations and longer follow-up study. Recently, mTOR inhibitor has been approved as a safe and efficacious molecular targeted drug for the treatment of SEGAs. However, SEGA can recur a few months after drug discontinuation. Long-term efficacy and safety of mTOR inhibitors should be evaluated with future studies.
